SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as the community rallies around the OG meme coin, anticipating potential listings and partnerships. Discussions are centered on community building and expressing bullish sentiment, emphasizing the coin's potential within the meme culture landscape. The community is actively participating in raids and spaces, further amplifying the coin's visibility.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is gaining attention as a multichain meme coin, with its community emphasizing its deflationary mechanism and organic growth. Discussions highlight its presence on multiple chains like Solana, CRO, and Base, with some suggesting staking opportunities may be coming. The community is actively using "caw caw caw" to express their excitement.

Bounce Token

Bounce Token is experiencing heightened interest as the community anticipates a potential breakout, drawing comparisons to previous rallies. Discussions revolve around promising utility, growing bid sizes, and possible integration with AI, with some community members pointing to bullish technical indicators. Despite some skepticism, there's optimism for a significant run, with attention focused on key price levels.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community discusses its potential, quantum-resistant technology, and real-world asset tokenization. Bullish sentiment is fueled by anticipation of alt season and speculation around partnerships, while some express frustration with the current price action and the Algorand Foundation. Chatter also includes commentary about specific users and their past predictions.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amid discussions about potential catalysts for Bitcoin, including possible government actions and favorable seasonal patterns. Community members are actively debating entry points and whether IBIT offers a better risk/reward profile compared to holding Bitcoin directly or investing in companies with Bitcoin on their balance sheets. Some traders are highlighting options activity suggesting bullish sentiment, while others remain cautious.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community discusses the project "crow with knife" ($CAW) and its potential impact on CRO. Some investors express frustration with CRO's price action and concerns about its performance relative to other cryptocurrencies, while others remain optimistic, citing potential catalysts and partnerships.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is trending as the community buzzes about its integration with Phantom Wallet, fueling excitement. Discussions highlight the potential for a breakout and "moon" run, with many claiming bags are loaded. Some users suggest caution, comparing it to other hyped coins.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst mixed sentiments, with some community members expressing frustration over its past performance while others remain optimistic, calling for patience and a focus on long-term potential. Discussions include potential price movements and comparisons to other meme coins. The broader conversation also touches upon the overall state of the crypto market and potential market manipulation.

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is trending as community members discuss its role in bridging and burning $CAW tokens across multiple blockchains. Some users highlight a recent acquisition deal with $ZRO, while others are drawn to Stargate's integration with Hyperliquid for one-click deposits. The community is actively bridging, burning, and following the crow with knife.

MLN is the official token of Enzyme. Founded in 2017, Enzyme is the global infrastructure for tokenized finance. Enzyme provides industry leaders with a comprehensive suites of Vault-As-A-Service and Financial Instruments products to manage on-chain assets efficiently, optimize operational processes, and develop innovative financial strategies tailored to their unique goals and challenges.

Melon

Recent price action and low supply are sparking increased interest in MLN, with some community members drawing comparisons to other coins with explosive growth potential. Conversations revolve around identifying potential entry points and anticipating a significant upward move. Some traders caution about potential pump and dump schemes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail buzz&nbsp;surrounding Applied Therapeutics Inc spiked&nbsp;late Sunday after the company revealed full 12-month clinical results alongside new 18- and 24-month topline data from&nbsp;a midstage trial of govorestat to treat Charcot-Marie-Tooth disease caused by Sorbitol Dehydrogenase deficiency (CMT-SORD).MRI observations showed that govorestat treatment slowed disease progression at 24 months, while keeping blood sorbitol levels low and improving functional outcomes and patient-reported metrics.The 12-month data revealed a statistically significant increase in the CMT-Health Index (CMT-HI) and a connection between sorbitol reductions and enhanced mobility and balance.&nbsp;CMT-SORD is a rare, progressive neuromuscular disorder that leads to nerve damage, muscle weakness, and mobility impairment.The company acknowledged that the primary endpoint of the 10MWRT at 12 months failed to show statistical significance, which led to its removal from the CMT-FOM clinical outcomes tool.Patients demonstrated good tolerance for govorestat, maintaining safety for two years.&nbsp;90% of eligible patients continued participating in the open-label extension study.&nbsp;Applied Therapeutics said it will submit a New Drug Application (NDA) for govorestat by 2025.The company’s shares surged 22.8% to close at $0.60 on Friday, with a further 1.2% gain in after-hours trading.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘a 629% surge in 24-hour message volume.Some retail traders expressed optimism about Applied Therapeutics' prospects, with one suggesting that the stock’s sharp decline in December may have been overdone and that the current low valuation presents a “monster opportunity.”<stembedurl>https://stocktwits.com/BuyThemCheapStackemDeep/message/615044473</stembedurl>Another pointed to the positive impact of govorestat on disease progression in CMT-SORD, noting that in a rare condition with no approved treatments, the available data could support regulatory approval.<stembedurl>https://stocktwits.com/Aawilliam2003/message/615043651</stembedurl>The stock has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug

The company said that Govorestat slowed disease progression and improved patient outcomes in CMT-SORD, a rare hereditary neuropathy. The company plans to submit an NDA in 2025 amid strong retail investor interest.

Equity

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Applied Therapeutics, Inc. (Applied Therapeutics or the Company) (NASDAQ: APLT) and reminds...

Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky

Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February...

INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT

INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc...

APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit

APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit APLT Deadline in 2 Days: Kessler Topaz...

APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit

APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc...

APLT Deadline: Rosen Law Firm Urges Applied Therapeutics, Inc. (NASDAQ: APLT) Investors to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between...

Deadline Soon: Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 18, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of...

Applied Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT

Applied Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT Applied...

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Applied Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.28
Prev Close	$1.25
Open	$1.23
Dividend Yield	0.00%
50-Day Moving Average	$0.6469
Beta	0.70
Avg. Volume	8.45M
PE Ratio	-2.88

52-Week High	$10.62
52-Week Low	$0.295
Market Capitalization	$184.34M
EPS (Annual)	-$0.757
Price to Book	10.42
Revenue Per Employee	$13,000.00
Enterprise Value/EBITDA	N/A

APLT
Applied Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest APLT News

APLTApplied Therapeutics Inc